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Abstract
Background: There is limited epidemiologic data on patients with acute myelogenous (myeloid) leukemia (AML)
requiring life-sustaining therapies in the intensive care unit (ICU). Our objectives were to describe the clinical
characteristics and outcomes in critically ill AML patients.
Methods: This was a retrospective case-control study. Cases were defined as adult patients with a primary
diagnosis of AML admitted to ICU at the University of Alberta Hospital between January 1
st 2002 and June 30
th
2008. Each case was matched by age, sex, and illness severity (ICU only) to two control groups: hospitalized AML
controls, and non-AML ICU controls. Data were extracted on demographics, course of hospitalization, and clinical
outcomes.
Results: In total, 45 AML patients with available data were admitted to ICU. Mean (SD) age was 54.8 (13.1) years
and 28.9% were female. Primary diagnoses were sepsis (32.6%) and respiratory failure (37.3%). Mean (SD) APACHE II
score was 30.3 (10.3), SOFA score 12.6 (4.0) with 62.2% receiving mechanical ventilation, 55.6% vasoactive therapy,
and 26.7% renal replacement therapy. Crude in-hospital, 90-day and 1-year mortality was 44.4%, 51.1% and 71.1%,
respectively. AML cases had significantly higher adjusted-hazards of death (HR 2.23; 95% CI, 1.38-3.60, p = 0.001)
compared to both non-AML ICU controls (HR 1.69; 95% CI, 1.11-2.58, p = 0.02) and hospitalized AML controls (OR
1.0, reference variable). Factors associated with ICU mortality by univariate analysis included older age, AML
subtype, higher baseline SOFA score, no change or an increase in early SOFA score, shock, vasoactive therapy and
mechanical ventilation. Active chemotherapy in ICU was associated with lower mortality.
Conclusions: AML patients may represent a minority of all critically ill admissions; however, are not uncommonly
supported in ICU. These AML patients are characterized by high illness severity, multi-organ dysfunction, and high
treatment intensity and have a higher risk of death when compared with matched hospitalized AML or non-AML
ICU controls. The absence of early improvement in organ failure may be a useful predictor for mortality for AML
patients admitted to ICU.
Background
Acute myelogenous (myeloid) leukemia (AML), a hema-
tologic malignancy characterized by clonal proliferation
of myeloblasts, is the most common type of leukemia in
adults and uniformly fatal without treatment [1]. Over
the past 20 years, more aggressive chemotherapeutic
regimens, availability of bone marrow transplantation
(BMT), and development of subtype-directed therapies
have led to improved survival [2]. However, these more
aggressive therapeutic strategies have also contributed to
a higher likelihood of complications [3,4], translating
into a greater demand for support in an intensive care
unit (ICU) setting [5-10]. Moreover, ICU support of
these patients has been associated with more intensive
and greater resource utilization [11].
A number of observational studies in patients with
hematologic malignancies admitted to ICU have
described the clinical outcomes and prognostic factors
for survival [5-8,11-22]. The majority of studies have
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have enrolled a mixed cohort of critically ill patients
with all forms of hematologic malignancy or who had
received a BMT.(Additional File 1) Few studies have
specifically investigated the ICU course in AML patients
[13,14,16,17]. Two primarily focused on AML patients
with pulmonary infiltrates requiring mechanical ventila-
tion, and reported a dismal ICU survival of 3-13%
[14,17]. In another study of 83 consecutive AML
patients, Rabbat et al reported 66% ICU survival and
33% 1-year survival [13]. In a cohort of 90 consecutive
patients admitted to ICU over 3-year surveillance, of
which 82% had a primary AML diagnosis, Thakkar et al
described poor 6 and 12 month survival of only 18%
and 16%, respectively [16]. Finally, Park et al described
68% hospital mortality in 50 acute leukemia patients,
70% with AML, admitted to ICU with septic shock [16].
However, clear inferences regarding prognosis for criti-
cally ill AML patients from these studies are limited due
to selection bias (i.e. only receiving mechanical ventila-
tion), inclusion of a mixed leukemia population (i.e.
acute lymphoblastic leukemia), or lack of controls for
comparison.
Accordingly, we performed a retrospective case-con-
trol study of patients with AML admitted to ICU. We
hypothesized that AML patients receiving ICU support
would have higher mortality when compared with
matched controls; however, that a considerable propor-
tion of these AML patients would survive to leave hos-
pital. Our objectives were to: 1) define the incidence of
ICU admissions with a primary diagnosis of AML; 2)
describe the clinical characteristics, course and treat-
ment intensity of ICU admissions with AML; and 3)
describe the short- and long-term outcomes of ICU
AML patients compared with matched non-AML ICU
patients and non-ICU AML hospitalized patients.
Methods
Study Design, Setting and Population
We performed a retrospective case-control study of
patients with acute myelogenous (myeloid) leukemia
(AML) admitted to the General Systems Intensive Care
Unit (GSICU) at the University of Alberta Hospital
between January 1
st, 2002 and June 30
th, 2008. Cases
were defined as adult patients (age ≥18 years) with a
confirmed diagnosis of AML and admission to the
GSICU. Each case was then matched with two control
groups: 1) non-ICU hospitalized patients with confirmed
AML (i.e. admitted to the medical/hematology ward;
matched 1:1); and subsequently to 2) non-AML critically
ill patients (i.e. admitted to the GSICU; matched 1:5).
The study protocol was approved by the Health Research
Ethics Board at the University of Alberta prior to
commencement.
Study Definitions
AML diagnosis was typed and characterized according
to the WHO and FAB classification schemes [23]. The
status of AML was categorized as: newly diagnosed/
active, refractory or relapse, in remission following
HSCT, or in remission. AML patients were also classi-
fied according to treatment regimen received: intensive
induction/consolidative chemotherapy, or cytoreductive
chemotherapy and/or palliation. Patients receiving
induction/consolidative chemotherapy for AML at our
institution do not routinely receive prophylactic antibio-
tic or antifungal therapy. Neutropenia was defined as an
absolute neutrophil count < 1.0 × 10
9 cells/L. When
patients develop an episode of febrile neutropenia (i.e.
documented temperature ≥38.3°C and ANC ≤1.0 cells/
10
9) empiric broad-spectrum antimicrobials are initiated.
The presence of co-morbid illness was determined and
quantified. Non-AML leukemia, lymphoma or solid
organ tumor were defined by confirmatory pathologic
investigations. Congestive heart failure (CHF) was
defined as the presence of New York Heart Association
(NYHA) class III or IV disease. Chronic lung disease
was defined as functional limitation or home oxygen
therapy attributable to documented lung pathology.
Chronic kidney disease (CKD) was defined as National
Kidney Foundation Kidney Disease Outcome Quality
Initiative (KDIGO) ≥ stage 4 disease. Liver disease was
defined as biopsy proven cirrhosis or elevated liver
enzymes attributable to active liver disease. Human
immunodeficiency virus (HIV) or acquired immunodefi-
ciency syndrome (AIDS) were defined by documented
HIV status and/or documented opportunistic infection/
illness attributable to HIV. Shock was defined by a
documented mean arterial pressure (MAP) ≤60 mmHg
and/or use of vasoactive therapy and an elevated serum
lactate. Illness severity was defined according to the
Acute Physiology and Chronic Health Evaluation
(APACHE) II score [24]. Baseline and changes to organ
failure were characterized by the Sequential Organ Fail-
ure Assessment (SOFA) score [25]. Acute kidney injury
(AKI) was defined as an acute rise in serum creatinine
≥150 μmol/L or urine output ≤400 mL/24 hr and no
documented CKD (≥ stage 4).
Study Protocol
Cases were identified by review of a local database of
consecutive new diagnoses of AML maintained by the
Department of Laboratory Medicine at the University of
Alberta Hospital. This database maintains detailed data
on the clinical and diagnostic characteristics of AML
patients (i.e. WHO classification, cytogenetic profile,
laboratory values at diagnosis). These AML patients
were subsequently cross referenced with an ICU-specific
database, the Minimal Data Set (MDS) database, which
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outcome data on all GSICU admissions. The linkage of
these two datasets enabled capture of “cases” of con-
firmed AML and GSICU admission. Each case was
subsequently matched to the two control groups. Non-
ICU hospitalized AML controls were randomly selected
from the AML database and matched for age (± 2 years)
and sex. Non-AML ICU controls were randomly
selected from the MDS dataset, and matched for age
(± 2 years), sex and APACHE II score (± 2 points) (ICU
cohort only).
Detailed data pertaining to demographics, clinical
characteristics, acute physiology, course in hospital, and
clinical outcomes were extracted from the medical
records of each patient and merged with data obtained
from the AML and MDS databases. Demographic and
baseline clinical data included age, sex, co-morbid dis-
ease, primary diagnosis, surgical status, and dates of
hospital/ICU admission and discharge. The characteris-
tics of AML were extracted from the AML database. For
cases and ICU controls, acute physiologic data, labora-
tory parameters, and clinical course, interventions,
including corticosteroids, AML-specific chemotherapy,
vasoactive therapy, mechanical ventilation and renal
replacement therapy (RRT) were recorded. SOFA scores
were ascertained at baseline and at days 1, 3 and 7 after
ICU admission.
The primary outcome of interest was the incidence of
ICU admissions for patientsw i t had i a g n o s i so fA M L ,
defined as a proportion (number of cases per number of
individual admissions) and as number of cases per 1000
ICU admissions. For patients with more than one ICU
admission within the same hospitalization, only the first
ICU episode was considered. Secondary outcomes of
interest included short-term (ICU/hospital) and long-
term (90-day, 1-year) survival, ICU/hospital lengths of
stay, changes in organ failure scores during the first
week in ICU (i.e. ΔSOFA), and measures of treatment
intensity (i.e. need for mechanical ventilation, vasoactive
therapy, and RRT). Tertiary outcomes included determi-
nation of factors associated with survival to discharge
from ICU.
Statistical Analysis
Clinical variables and univariate comparison between
groups are reported as means with standard deviations
(SD) for normally or near normally distributed variables
a n dc o m p a r e du s i n gS t u d e n t ’st - t e s to ra n a l y s i so fv a r -
iance (ANOVA); non-normally distributed continuous
data is reported as medians with inter-quartile ranges
(IQR) and compared using Mann Whitney U test or
Kruskal Wallis test, as appropriate. Categorical data are
reported as proportions and compared using Fisher’s
Exact Test. Crude survival stratified by study group was
assessed graphically by the Kaplan-Meier product limit
estimator and compared with the log-rank test. Cox
proportional hazards analysis was used to evaluate
the association between AML cases and controls and
mortality. Data are presented as crude and covariate-
adjusted hazard ratios (HR) and 95% confidence inter-
vals (CI). Plots of log (-log [survival]) versus log (survival
time) were constructed to evaluate the assumption of
proportionality. Univariate analysis of AML cases was
performed to evaluate for clinical factors associated
with ICU survival. Intercooled Stata Release 10.2 (Stata
Corp, TX) was used for all data analysis. A p-value of
<0.05 was considered statistically significant for all
comparisons.
Results
The baseline demographics and clinical features of
patients stratified by group are shown in Table 1. There
were 386 patients diagnosed with AML during the study
period. A total of 50 AML patients, representing 13% of
all new AML diagnoses, were admitted to ICU. This
represented an estimated incidence of 0.74% of all ICU
admissions (n = 6,801) or 7.4 AML patients per 1000
ICU admissions. The medical records for five of these
AML ICU patients could not be retrieved for detailed
review; therefore, these patients were omitted from
further analysis.
Demographic, Clinical and Diagnostic Characteristics of
AML
AML cases had a mean (SD) age of 54.8 (13.1) years,
28.9% were female, and had a median (IQR) one (0-2)
co-morbid illness (Table 1). There were no statistical
differences in the AML classification, cytogenetic profile
or therapeutic regimen between AML cases and controls
(Table 2). There were more AML cases classified as
remission when compared with AML controls. Of these,
four had received HSCT after intensive chemotherapy.
The median (IQR) duration from AML diagnosis to ICU
admission was 46 days (12-251). This duration was
shortest in newly diagnosed or those with active disease
(17 days [2-28]) and in those in remission post-HSCT
(93 [88-964]) compared to those with refractory/
relapsed disease (323 [144-743]) or remission following
chemotherapy alone (280 [102-436]) (p = 0.0001).
Baseline Characteristics, Physiology and Laboratory
Parameters in ICU
AML cases, when compared to ICU controls, had a
higher rate of admission for sepsis and a non-significant
but higher rate for respiratory failure (Table 3). Only one
AML case (2.2%) was post-operative, compared with
23.6% of ICU controls (p < 0.001). As expected, there
was no significant difference in mean (SD) APACHE II
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cases had a lower GCS score (p = 0.0003), higher tem-
perature (p = 0.05), higher heart rate p = 0.001), and
respiratory rate (p < 0.0001) when compared with ICU
controls.
Treatment Intensity and Course in ICU for AML patients
AML cases were significantly less likely to receive
mechanical ventilation (p = 0.003) despite comparable
or low PaO2/FiO2 ratios. Of AML cases, 88.4% pre-
sented with shock, and 75.6% were supported with
vasoactive therapy. Acute kidney injury occurred in
53.5% with 47.8% of these patients subsequently receiv-
ing support with acute RRT. In total, 97.8% received
broad-spectrum antimicrobials, 86.7% received trans-
fused blood products, 48.9% received replacement corti-
costeroids, 51.2% received G-CSF and 15.6% received
AML-specific chemotherapy while in ICU. At the time
of ICU admission, 93.3% were designated as full resusci-
tation, however, 47.6% later had their status changed to
not for resuscitation (NFR) while in ICU. Of the 17 ICU
deaths in AML patients, 88.2% occurred in those with a
change in NFR status (p < 0.0001 compared with ICU
mortality for no change in NFR status).
Survival, Lengths of Stay and Discharge Disposition
Crude survival at hospital discharge, 28-days, 90-days and
1-year was lower for AML cases compared with both
AML and ICU controls (Table 4, Figure 1). At 1-year,
survival among AML cases was 28.9%, compared with
52.0% and 54.0% for AML and ICU controls, respec-
tively (p = 0.03). The median survival for AML cases
admitted to ICU was 82 days (95% CI, 14-700), and
was significantly lower than for AML and ICU controls
(Table 4). By Cox survival analysis, AML cases had a
significantly higher adjusted-hazards ratio (HR) for
death (HR 2.23; 95% CI, 1.38-3.60) compared with
both ICU (HR 1.69; 95% CI 1.11-2.58) and AML con-
trols (HR 1.0, reference) (Table 5). ICU and hospital
stay were non-significantly longer for AML cases sur-
viving to ICU and hospital discharge (Table 5). In
total, 46.7% of AML cases survived hospitalization and
were discharged home compared with 40.9% of
ICU controls (p = 0.32) and 62.0% of AML controls
(p = 0.15). By Cox survival analysis, the adjusted-HR of
death, conditional on survival to hospital discharge, was
significantly higher for AML cases (HR 2.46; 95% CI,
1.4-4.3, p = 0.002) compared to either AML controls
(HR 1.40; 95% CI, 0.85-2.30, p = 0.19) or ICU controls
(HR 1.0, reference).(Figure 2).
Prognostic Factors for AML Patients in ICU
For AML cases, several factors were found to be associated
with ICU mortality by univariate analysis (Table 6 Older
age, AML subtype M1, higher organ failure score, shock,
vasoactive therapy, mechanical ventilation were all
Table 1 Summary of baseline demographic and clinical features of patients stratified by group
Variable Total
(n = 320)
AML ICU Cases
(n = 45)
AML non-ICU Controls
(n = 50)
Non-AML ICU Controls
(n = 225)
p-value
Age (mean [SD]) (years) 54.6 (13.7) 54.8 (13.1) 53.4 (16.2) 54.8 (13.2) 0.75
Female sex (%) 91 (28.4) 13 (28.9) 11 (22.0) 67 (29.8) 0.56
BMI (mean [SD]) (kg/m
2) 29.3 (7.1) 30.7 (6.6) 29.8 (6.4) 27.0 (7.9) 0.13
Co-morbid disease type (%)
Leukemia 102 (31.9) 45 (100) 50 (100) 7 (3.1) <0.001
Lymphoma 5 (1.6) 2 (2.2) 0 (0) 4 (1.8) 0.81
Solid organ tumor 8 (2.5) 1 (2.2) 0 (0) 7 (3.1) 0.64
Congestive heart failure 11 (3.4) 1 (2.2) 3 (6.0) 7 (3.1) 0.62
Chronic lung Disease 16 (5.0) 0 (0) 3 (6.0) 13 (5.8) 0.28
Chronic kidney disease 19 (5.9) 0 (0) 2 (4.0) 17 (7.6) 0.13
Liver disease 41 (12.8) 1 (2.2) 2 (4.0) 38 (16.9) 0.002
HIV/AIDS 5 (1.6) 0 (0) 1 (2.0) 4 (1.8) 1.0
Co-morbid disease (%)
¶
None (%) 143 (44.7) 24 (53.3) 0 (0) 119 (52.9) <0.001
1 149 (46.6) 19 (42.2) 41 (82.0) 89 (39.6)
2 26 (8.1) 2 (4.4) 7 (14.0) 17 (7.6)
≥3 2 (0.6) 0 (0) 2 (4.0) 0 (0)
Surgical admission (%) 54 (16.9) 1 (2.2) 0 (0) 53 (23.6) <0.001
Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome.
§ Included prior myocardial infarction, congestive heart failure, and/or peripheral vascular disease.
¶ Co-morbid disease excluding AML diagnosis.
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AML patients receiving AML-specific chemotherapy while
in ICU had higher survival. The absence of change or wor-
sening in organ failure score in the first three days after
ICU admission was also associated with lower survival
(Figure 3). In this cohort, no significant association was
found between 90-day survival and co-morbid illness,
cytogenetic profile, time from AML diagnosis to ICU
admission, relapse or refractory AML status, primary sep-
tic diagnosis, or RRT.
Discussion
We conducted a 6.5-year retrospective matched case-
control study to compare the clinical characteristics,
course, and outcomes of patients with AML admitted to
ICU compared with non-critically ill hospitalized AML
controls and non-AML critically ill controls.
Our data have several relevant findings. First, while
AML patients represent only a minority of all ICU
admissions, we found that life threatening illness
prompting ICU admission is not uncommon, occurring
Table 2 Summary of diagnostic characteristics of AML
Variable Total
(n = 95)
AML ICU Cases
(n = 45)
AML non-ICU Controls
(n = 50)
p-value
AML WHO classification (n = 91)
AML with recurrent genetic abnormalities 44 (46.3) 19 (42.2) 25 (50.0) 0.18
AML with multi-lineage dysplasia 17 (17.9) 10 (22.2) 7 (14.0)
AML and myelodysplastic syndromes, therapy-related 6 (6.3) 5 (11.1) 1 (2.0)
AML not otherwise categorized 28 (29.5) 11 (24.4) 17 (34.0)
AML FAB Classification (n = 71)
M0 4 (4.2) 0 (0) 4 (8.0) 0.12
M1 28 (29.5) 15 (33.3) 13 (26.0)
M2 20 (21.1) 11 (24.4) 9 (18.0)
M3 12 (12.6) 3 (6.7) 9 (18.0)
M4 12 (12.6) 4 (8.9) 8 (16.0)
M4eo 5 (5.3) 4 (8.9) 1 (2.0)
M5 13 (13.7) 7 (15.6) 6 (12.0)
M6 1 (1.1) 1 (2.2) 0 (0)
Cytogenetic prognosis
§ (%)
Good 13 (13.7) 6 (13.3) 7 (14.0) 0.96
Intermediate 38 (40.0) 17 (37.8) 21 (42.0)
Poor 14 (28.0) 13 (28.9) 14 (28.0)
Unknown/not available 8 (16.0) 9 (20.0) 8 (16.0)
Complete blood count at diagnosis:
Hemoglobin (g/L) 96.7 (22.1) 95.9 (21.6) 97.3 22.6) 0.76
Platelets (cells/10
9) 46 (26-96) 45 (31-96) 47 (24-96) 0.46
White cell count (WBC) (cells/10
9) 8.2 (2.3-50.6) 7.7 (2.0-50.8) 16.0 (3.2-42.9) 0.87
WBC < 1 (%) 6 (7.1) 3 (6.7) 3 (6.0) 1.0
WBC > 25 (%) 34 (35.8) 15 (33.3) 19 (38.0) 0.67
Duration of Neutropenia (days) (mean [SD]) 14.1 (14.3) 13.1 (14.4) 15.2 (14.2) 0.48
Bone marrow blast count (%) 56.6 (23.7) 52.9 (23.7) 60.1 (23.5) 0.15
Blasts >20% 86 (94.5) 41 (93.2) 45 (95.7) 0.67
AML Status
Newly diagnosed/active disease 58 (61.1) 24 (53.3) 34 (68.0) 0.01
Refractory/relapse 29 (30.5) 13 (28.9) 16 (32.0)
BMT/remission 4 (4.2) 4 (8.9) 0 (0)
Remission 4 (4.2) 4 (8.9) 0 (0)
Therapeutic Regimen
Intensive/induction chemotherapy 78 (82.1) 38 (84.4) 40 (80.0) 0.60
Cytoreductive/palliative 17 (17.9) 7 (15.6) 10 (20.0)
Abbreviations: WHO = World Health Organization; FAB = French American British; WBC = white blood cell count.
§ Cytogenetic Prognosis: Good = t(8;21); t(15;17); inv16 or t(16;16); Intermediate = normal; trisomy 8; 11q23 abnormality; Poor = deletion of chromosome 5 or 5q;
deletion of chromosome 7 or 7q; 3q abnormality; complex; Unknown = significance not known; no cytogenetic information.
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these critically ill AML patients had predominantly sep-
tic and/or respiratory-related diagnoses and exhibited a
high acuity of illness, with the majority presenting with
shock. Moreover, AML patients had greater severity of
organ dysfunction. Third, AML patients were less likely
to receive mechanical ventilation; yet overall they
received high intensity support that included vasoactive
therapy in 75.6% and RRT in 26.7%, respectively. This
translated into longer, though non-significant, stays in
ICU and hospital. Fourth, we also found critically ill
AML patients had lower adjusted-survival when
compared with controls. By univariate analysis, several
factors were associated with a lower probability of survi-
val, including older age, AML M1 subtype, higher base-
line SOFA score, presence of shock, vasoactive therapy
and mechanical ventilation. We also found that worsen-
ing SOFA score early after ICU admission correlated
with lower survival. Alternatively, receipt of AML-speci-
fic chemotherapy while in ICU correlated with higher
survival. Finally, changes in patient resuscitation status
(i.e. to NFR) and withdrawal of support were both sig-
nificantly associated with higher likelihood of death at
90-days.
Table 3 Summary of ICU admission characteristics, acute physiology, and laboratory parameters stratified by AML status
Variable Total
(n = 275)
AML ICU Cases
(n = 45)
Non-AML ICU Controls
(n = 225)
p-value
Admission diagnostic category (%)
§
Sepsis/Infectious 53 (19.8) 14 (32.6) 39 (17.3) 0.04
Respiratory 70 (26.1) 16 (37.2) 54 (24.0) 0.09
Genitourinary 7 (2.6) 0 (0) 7 (3.1) 0.60
Gastrointestinal 50 (18.7) 1 (2.3) 49 (21.8) 0.001
Cardiovascular 27 (10.1) 1 (2.3) 26 (11.6) 0.09
Neurologic 15 (5.6) 2 (4.7) 13 (5.8) 1.0
Endocrine/Metabolic 13 (4.9) 0 (0) 13 (5.8) 0.14
Trauma 22 (8.2) 0 (0) 22 (9.8) 0.03
Other 11 (4.1) 9 (20.9) 2 (0.9) <0.001
APACHE II score (mean [SD]) 29.1 (9.9) 30.3 (10.3) 28.9 (9.9) 0.39
APACHE II score > 25 (%) 185 (68.5) 35 (77.8) 150 (66.7) 0.16
SOFA score (mean [SD]) 11.7 (4.6) 12.6 (4.0) 10.8 (4.9) 0.05
SOFA score > 11 (%) 55 (57.9) 32 (71.1) 23 (46.0) 0.02
Mechanical ventilation (%) 225 (83.3) 30 (66.7) 195 (86.7) 0.003
Acute physiology
GCS (mean [SD]) 7.6 (3.4) 5.9 (3.4) 7.9 (3.3) 0.0003
Temperaturemax (mean [SD]) (degrees C) 37.4 (3.6) 38.4 (1.2) 37.2 (3.8) 0.05
Heart ratemax (mean [SD]) (/min) 118 (23.4) 128 (18) 116 (24) 0.001
Respiratory ratemax (mean [SD]) (/min) 28 (8) 34 (8) 26 (8) <0.0001
Mean arterial pressuremin (mean [SD]) (mmHg) 59 (17) 60 (17) 59 (17) 0.74
Laboratory parameters
Hematocrit (mean [SD]) 26.6 (6.7) 22.6 (5.0) 27.3 (6.7) <0.0001
White blood cell count (med [IQR]) (10
9 cells/mL) 7.8 (4.2-13.1) 0.6 (0.2-7.5) 9.1 (4.8-13.6) <0.0001
Bilirubin (med [IQR]) (μmol/L) 23 (14-49) 33 (19-48) 22 (13-52) 0.26
PaO2/FiO2 ratio (mean [SD]) 174 (97) 158 (85) 177 (99) 0.22
pH (mean [SD]) 7.25 (0.15) 7.30 (0.13) 7.24 (0.15) 0.03
Serum Sodium (mean [SD]) (mmol/L) 137 (6.0) 137 (7.0) 137 (5.8) 0.63
Serum Creatinine (med [IQR) (μmol/L) 168 (93-284) 145 (97-203) 170 (89-318) 0.13
Urine output (med [IQR]) (L/24 hr) 1.3 (0.4-2.5) 2.2 (1.0-3.1) 1.2 (0.4-2.4) 0.0006
Urine output <400 mL (%) 61 (22.9) 3 (7.0) 58 (25.9) 0.005
Acute kidney injury (%) 138 (52.7) 23 (53.5) 115 (52.5) 1.0
Abbreviations: SOFA = sequential organ failure assessment; APACHE = acute physiology and chronic health evaluation; GCS = Glasgow coma score; ANC =
absolute neutrophil count.
§ Sum exceeds 100% due to more than one primary diagnosis.
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to patients with AML requiring life-sustaining measures
in the ICU. (Additional File 1) While numerous small
series have reported on the clinical outcomes for
patients with all forms of hematologic malignancy
admitted to ICU, very few have focused on AML, and
fewer still have provided estimates of incidence
[13,14,16,17]. During a 5-year surveillance, Tremblay et
al reported that among 163 consecutive hospitalized
AML patients, with a range in AML status (including 38
having received a HSCT), only 32 were admitted to ICU
and supported with mechanical ventilation (cumulative
incidence 19.6%) [17]. We observed a lower cumulative
incidence, with just over 1 in 10 of all newly diagnosed
AML patients being supported in ICU; moreover, we
observed that AML patients comprised <1% of all ICU
admissions during the study period. In a 4-year retro-
spective study, Merz et al reported on 101 ICU admis-
sions (n = 84) with hematologic malignancies, of which
54.4% had a diagnosis of AML [11]. These AML
admissions represented approximately 1.4% of all “emer-
gent and medical” ICU admissions.
Among AML patients admitted to ICU, the in-hospi-
tal, 90-day and long-term adjusted-survival were
observed to be lower when compared with either hospi-
talized AML or ICU controls. To our knowledge, this is
the first study to evaluate the long-term survival experi-
ence of critically ill AML patients compared with
matched controls. When compared with an unmatched
convenience sample of non-AML critically ill patients,
Tremblay et al found AML patients requiring mechani-
cal ventilation to clearly have higher in-hospital mortal-
ity [17]. Merz et al found in-hospital mortality
noticeably higher for ICU admissions associated with
hematologic malignancies compared with unmatched
controls (33.7% vs. 10.7%, p < 0.0001) [11]. In general,
the observed survival in our study is largely consistent
with prior studies, where estimates of ICU, in-hospital
and 1-year survival were 12-70%, 3-64%, and 0-34%,
respectively [12-14,16,17,20,21,26-34]. The median survi-
val of critically ill AML patients in our cohort was only
about three months, in contrast to approximately nine
months for the control groups. While the majority of
deaths in AML patients occurred early after ICU admis-
sion (median duration 5 days), the adjusted risk of death
remained significantly higher during follow-up com-
pared with either control group. These data would sug-
gest, in general, that AML patients developing an
episode of critical illness prompting ICU support have a
less favorable outcome compared with hospitalized
AML and non-AML ICU patients.
Prior data imply AML patients supported in ICU have
greater health resource utilization. This was shown by
Merz et al, who described considerably higher ICU
resource use by hemato-oncological patients, as mea-
sured by the Therapeutic Interventions Scoring System
Table 4 Summary of clinical outcomes stratified by group
Outcome Total
(n = 145)
AML ICU Cases
(n = 45)
AML non-ICU Controls
(n = 50)
Non-AML ICU Controls
(n = 225)
p-value
ICU death (%) 83 (30.7) 17 (37.8) - 66 (29.3) 0.29
Hospital death (%) 121 (37.8) 20 (44.4) 9 (18.0) 92 (40.9) 0.004
28-Day death (%) 98 (30.6) 17 (37.8) 8 (16.0) 73 (32.4) 0.03
90-Day death (%) 132 (41.3) 23 (51.1) 16 (32.0) 93 (41.3) 0.17
1-Year death (%) 178 (55.6) 32 (71.1) 27 (54.0) 119 (52.9) 0.08
ICU length of stay (days) 4 (2-11) 5 (2-12) - 4 (2-11) 0.38
Survived 5 (2-12) 8 (2-14) - 5 (3-11) 0.44
Dead 2 (1-5) 4 (1-7) - 1 (1-3) 0.17
Hospital length of stay (days) 15 (6-39) 22 (11-47) 24 (9-35) 13 (5-36) 0.12
Survived 21 (10-45) 37 (18-50) 25 (12-35) 17 (10-44) 0.22
Dead 14 (9-28) 13 (9-19) 6 (1-28) 3 (1-12) 0.17
Median survival (95% CI) (days) 207 (14-2442) 82 (14-700) 274 (55-1303) 258 (9-2442) 0.01
Figure 1 Crude K-M survival estimates by group (truncated at
1000 days).
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Page 7 of 12(TISS) (214 vs. 95, p < 0.0001) and ICU length of stay
(2.0 vs. 1.1 days, p < 0.02), compared with emergent
medical ICU patients [11]. Despite no difference in the
rates of mechanical ventilation or RRT between groups,
both of these interventions showed significant correla-
tion with total ICU resource use. This also translated
into greater total direct costs per ICU admission for
hemato-oncological patients. While our study did not
incorporate a formal cost analysis, AML patients in our
study had non-significant, but longer observed stays in
both ICU and hospital. Interestingly, our data found sig-
nificantly fewer AML patients received mechanical ven-
tilation, despite evidence of similar or worst lung injury.
This observation may, in part, be attributable to prior
data correlating less favorable prognosis for these
patients requiring mechanical ventilation [17,22,28,35].
These data also suggest greater health resource use for
AML patients; however, there is little data on whether
this is balanced by higher quality-adjusted survival of
ICU admissions with hematologic malignancy. In a
small series of 92 critically ill patients with hematologic
malignancy, Yau et al described the quality-of-life as
acceptable or good in the 7 survivors (7.6%) at 1-year,
with no patient reporting significant limitations to daily
activities [34].
Few data have explored the long-term disposition of
AML patients after life-threatening critical illness. Inter-
estingly, despite lower overall survival, 46.7% of all AML
patients supported in ICU in our study survived hospita-
lization to be discharged home (or 84.0% of survivors).
This was statistically comparable to hospitalized AML
and ICU controls.
The characterization of potential factors predictive of
survival for hematologic malignancy patients prior
to and/or early after ICU admission has been the focus
of considerable research effort [12,13,16,20,22,26,28,
30-32,35]. Several factors have been suggested to predict
non-survival at various time points across a range of
studies including: older patient age [14], poor perfor-
mance status [13], AML subtype [13], relapsed/refrac-
tory AML status [22], poor cytogenetic profile [16],
higher illness severity or organ failure score
Table 5 Cox proportional hazards survival analysis
stratified by group
Group Crude HR
(95% CI)
Adjusted
§ HR
(95% CI)
AML controls 1.0
¶ 1.0
¶
ICU controls 1.24 (0.84-1.83) 1.69 (1.11-2.58)
AML cases 2.12 (1.31-3.43) 2.23 (1.38-3.60)
Abbreviations: AML = acute myelogenous leukemia; ICU = intensive care unit;
CI = confidence interval.
§ Cox PH model adjusted for: age, sex, co-morbid disease, surgical status.
¶ Reference variable.
Figure 2 Crude K-M survival estimates by group conditional on survival to hospital discharge (truncated at 1000 days).
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Page 8 of 12[13,16,18,22,31,32], leukopenia [12], vasopressor therapy
[12,16,22], mechanical ventilation [13,16,22], acute kid-
ney injury [12], absence of bloodstream infection
[12,27], and fungal sepsis [3 2 ] .I no u rc o h o r t ,w ef o u n d
that older age, AML M1 subtype, higher organ failure
score, the presence of shock, vasopressors therapy, and
mechanical ventilation were all associated with lower
survival. There was no association between survival and
cytogenetic profile, therapeutic regimen or burden of
co-morbid illness. However, these prognostic factors
have been inconsistent and not readily reproducible, due
largely to issues related to study design (i.e. small, single
centre, retrospective, no controls, analysis) and lack of
generalizability (i.e. selection bias, mixed hematologic
populations). Of note, we also found receipt of active
intensive chemotherapy while in ICU was associated
with higher observed survival. Recently, Vandijck et al
reported that active chemotherapy was associated with
better ICU survival in a cohort of 77 patients admitted
to ICU with severe sepsis or septic shock [18]. These
observations would suggest that prognosis for AML
patients receiving active chemotherapy may be better
than perceived.
Perhaps no constellation of disease or treatment-speci-
fic factors will consistently predict outcome for all AML
patients developing life-threatening critical illness. As
such, it may be that prognostic factors may have a lim-
ited role in the decision to admit an AML patient to
ICU. Indeed, hospital survival in our study was 55.6%,
with 84.0% of survivors returning home and 29.9% alive
at 1-year. Instead, prognostic factors may have greater
relevance for decisions regarding the withholding of life-
sustaining therapies and in end-of-life care. For example,
worsening illness severity and/or organ dysfunction early
after ICU admission has been found to predict poor
clinical outcome [11,31,32]. Massion et al showed an
improvement in Multi-Organ Dysfunction Score
(MODS) of ≤1 point between ICU admission and day 5
correlated with increased mortality (81% vs. 29%, p =
0.001) [32]. Merz et al described significant higher 28-
day mortality for patients with worsening SOFA score
over the first 48 hours (OR 24.4, 95% CI, 8.8-67.9, p <
0.0001) [11]. Finally, Lamia et al showed worsening Sim-
plified Acute Physiology Score (SAPS) II score, Logistic
Organ Dysfunction score (LODS), and SOFA score dur-
ing the first three days after ICU admission to be the
best predictors of in-hospital mortality [31]. Our study
further confirmed these observations. We found that the
absence of change or an increase in organ failure score
early after ICU admission correlated with lower survival.
Table 6 Univariate factors associated with 90-day
mortality in patients with AML
Characteristic 90-Day Status p-value
Dead
(n = 25)
Alive
(n = 20)
Age (mean [SD]) 59.4 (11.7) 49.8 (12.9) 0.01
≥2 co-morbidities (%) 12 (52.2) 9 (40.9) 0.55
AML M1 Subtype (%) 12 (48.0) 3 (15.0) 0.03
Poor cytogenetic profile (%) 6 (26.1) 7 (31.8) 0.75
Time from AML diagnosis
to ICU (d)
65 (12-288) 40 (9-95) 0.61
Relapse/refractory AML status
(%)
8 (32.0) 5 (25.0) 0.75
Duration of neutropenia (d)
(med [IQR])
15 (13-19) 15 (13-19) 0.80
Chemotherapy in ICU (%) 1 (4.0) 6 (30.0) 0.03
Sepsis diagnosis (%) 8 (32.0) 6 (33.3) 1.0
APACHE II score (mean [SD]) 32.4 (10.7) 28.0 (9.5) 0.15
SOFA score (mean [SD]) 14.6 (4.3) 11.4 (3.3) 0.007
Delta SOFA (day 1) (med [IQR]) 1 (0 to 3) 0 (-2 to 2) 0.02
Delta SOFA (day 3) (med [IQR]) 2 (-1 to 4) -2 (-4 to 2) 0.02
SOFA (maximum) (mean [SD]) 12.1 (5.3) 10.8 (3.1) 0.46
MAP <60 mmHg (%) 11 (44.0) 4 (22.2) 0.20
Lactate (mmol/L) (mean [SD]) 4.1 (4.6) 2.1 (1.7) 0.08
Vasoactive therapy (%) 22 (88.0) 12 (60.0) 0.04
Shock (%) 25 (100) 13 (72.2) 0.009
Platelets (10
9 cells/L) (med [IQR]) 17 (9-37) 14 (10-31) 0.90
Bilirubin (μmol/L) (mean [SD]) 40.5 (37.3) 31.1 (15.7) 0.30
P/F ratio (mean [SD]) 116 (88) 149 (100) <0.001
Mechanical ventilation (%) 21 (84.0) 9 (45.0) 0.01
Creatinine (μmol/L) (mean [SD]) 148 (59) 176 (108) 0.28
Renal replacement therapy (%) 7 (28.0) 5 (25.0) 1.0
G-CSF (%) 17 (68.0) 9 (47.4) 0.22
Corticosteroids (%) 13 (52.0) 9 (47.4) 1.0
Withdrawal of support (%) 16 (64.0) 0 (0) <0.001
Abbreviations: d = days; SOFA = sequential organ failure assessment; APACHE =
acute physiology and chronic health evaluation; MAP = mean arterial pressure;
P/F = PaO2/FiO2; G-CSF = granulocyte colony-stimulating factor.
Figure 3 Δ SOFA score over first 7 days in ICU stratified by 90-
day survival.
Roze des Ordons et al. BMC Cancer 2010, 10:516
http://www.biomedcentral.com/1471-2407/10/516
Page 9 of 12Furthermore, we found that a change in patient resus-
citation status from full resuscitation to not for resusci-
tation (NFR) and withdrawal of active support were
common and both significantly modified the observed
mortality at 90-days. In a series of 124 consecutive criti-
cally ill hematological malignancy patients, Benoit et al
found 4% had a NFR order written within 24 hours of
ICU admission, while 20.2% had a NFR order written
after a median 7 days in ICU [12]. In our study, only
6.7% of AML ICU patients had a NFR order at presenta-
tion, whereas an additional 46.7% had their status later
changed to NFR while in ICU. While we did not specifi-
cally examine the timing of this change, decisions about
withholding life-sustaining measures in our study may
have related to higher or worsening organ failure score
and need for escalation in treatment intensity (i.e.
vasoactive therapy, mechanical ventilation, RRT). We
did not find association between change in resuscitation
status and age, co-morbidity score, AML subtype, poor
AML cytogenetic prognosis, or duration of ICU stay.
We recognize one plausible explanation for this finding
may relate to a clinician perception of poor clinical out-
come and/or general reluctance to pursue aggressive
and/or prolonged life sustaining measures for AML
patients [36].
There are important limitations to our study. First,
our study was single-centered and retrospective in
design and was therefore potentially susceptible to bias.
For example, we were unable to determine whether
AML patients designated as “non-ICU” had end-of-life
discussions that precluded admission to ICU, despite
comparable “critical illness”, which would unduly influ-
ence our incidence estimate (i.e. selection bias). How-
ever, we have attempted to minimize this by showing no
significant differences in the therapeutic regiments
received by AML cases and controls. Second, despite
over 6 years of surveillance for AML patients admitted
to our ICU, our sample was small and provided limited
statistical power; we therefore omitted multi-variable
analysis for determination of predictors of survival. To
compensate, we further matched AML patients based
on age, sex and APACHE II score (ICU only). While we
did not a priori match AML groups for cytogenetic pro-
file or therapeutic regimen received, we found no statis-
tical differences between the AML cases and controls.
Third, we endeavored to match the final cohort of AML
cases with non-AML ICU controls by a ratio of 1:5;
however, we recognize these ICU controls still represent
a heterogeneous population and, despite similar illness
severity, have observed differences that may impact out-
come (i.e. primary diagnosis, prevalence of co-morbid
illness). Finally, we were not able to ascertain additional
secondary outcomes of relevance to survivors, such as
health-related quality of life or functional status and the
details of ongoing care requirements, which may also
have prognostic significance [34].
Conclusions
In summary, AML patients may represent a minority of
all critically ill admissions; however, are not uncommonly
supported in ICU. These AML patients are characterized
by high illness severity, multi-organ dysfunction, and
high treatment intensity and have a higher risk of death
when compared with matched hospitalized AML or non-
AML ICU controls. Critically ill AML patients also have
greater long-term mortality, which may be associated
with severe clinical and disease-specific factors including
absence of improvement in organ dysfunction early after
ICU admission. Despite lower survival; however, our data
imply a significant proportion of these critically ill AML
patients survive hospitalization and are discharged home.
We contend that additional multi-centre prospective stu-
dies are needed to further characterize these outcomes in
AML patients suffering an episode of life-threatening cri-
tical illness.
Key messages
￿ Approximately 1 in 10 patients newly diagnosed
with AML develop life-threatening critical illness
prompting life-sustaining therapy in ICU.
￿ AML patients admitted to ICU have greater organ
dysfunction, higher treatment intensity and use more
health resources compared with matched controls.
￿ AML patients admitted to ICU have higher short-
and long-term mortality compared with matched
controls.
￿ Early absence of change or an increase in organ fail-
ure score following admission to ICU was associated
with lower likelihood of survival for AML patients.
￿ Despite the higher mortality observed for AML
patients admitted to ICU compared with matched
controls, a significant proportion of them survive
and are discharged home.
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